158 related articles for article (PubMed ID: 10196269)
1. Protection against establishment of retroviral persistence by vaccination with a live attenuated virus.
Dittmer U; Brooks DM; Hasenkrug KJ
J Virol; 1999 May; 73(5):3753-7. PubMed ID: 10196269
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms.
Dittmer U; Brooks DM; Hasenkrug KJ
J Virol; 1998 Aug; 72(8):6554-8. PubMed ID: 9658099
[TBL] [Abstract][Full Text] [Related]
3. Different immunological requirements for protection against acute versus persistent Friend retrovirus infections.
Dittmer U; Hasenkrug KJ
Virology; 2000 Jun; 272(1):177-82. PubMed ID: 10873760
[TBL] [Abstract][Full Text] [Related]
4. Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection.
Dittmer U; Brooks DM; Hasenkrug KJ
Nat Med; 1999 Feb; 5(2):189-93. PubMed ID: 9930867
[TBL] [Abstract][Full Text] [Related]
5. The role of IL-5, IL-6 and IL-10 in primary and vaccine-primed immune responses to infection with Friend retrovirus (Murine leukaemia virus).
Strestik BD; Olbrich ARM; Hasenkrug KJ; Dittmer U
J Gen Virol; 2001 Jun; 82(Pt 6):1349-1354. PubMed ID: 11369878
[TBL] [Abstract][Full Text] [Related]
6. Peptide-induced immune protection of CD8+ T cell-deficient mice against Friend retrovirus-induced disease.
Kawabata H; Niwa A; Tsuji-Kawahara S; Uenishi H; Iwanami N; Matsukuma H; Abe H; Tabata N; Matsumura H; Miyazawa M
Int Immunol; 2006 Jan; 18(1):183-98. PubMed ID: 16352628
[TBL] [Abstract][Full Text] [Related]
7. Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection.
Dittmer U; Peterson KE; Messer R; Stromnes IM; Race B; Hasenkrug KJ
J Virol; 2001 Jan; 75(2):654-60. PubMed ID: 11134279
[TBL] [Abstract][Full Text] [Related]
8. Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery.
Kaulfuß M; Wensing I; Windmann S; Hrycak CP; Bayer W
Retrovirology; 2017 Feb; 14(1):8. PubMed ID: 28166802
[TBL] [Abstract][Full Text] [Related]
9. Identification of a protective CD4+ T-cell epitope in p15gag of Friend murine leukemia virus and role of the MA protein targeting the plasma membrane in immunogenicity.
Sugahara D; Tsuji-Kawahara S; Miyazawa M
J Virol; 2004 Jun; 78(12):6322-34. PubMed ID: 15163726
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies.
Bayer W; Schimmer S; Hoffmann D; Dittmer U; Wildner O
Vaccine; 2008 Jan; 26(5):716-26. PubMed ID: 18160188
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.
Bayer W; Tenbusch M; Lietz R; Johrden L; Schimmer S; Uberla K; Dittmer U; Wildner O
J Virol; 2010 Feb; 84(4):1967-76. PubMed ID: 20007267
[TBL] [Abstract][Full Text] [Related]
12. Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses.
Schlecht-Louf G; Renard M; Mangeney M; Letzelter C; Richaud A; Ducos B; Bouallaga I; Heidmann T
Proc Natl Acad Sci U S A; 2010 Feb; 107(8):3782-7. PubMed ID: 20142478
[TBL] [Abstract][Full Text] [Related]
13. Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.
Messer RJ; Dittmer U; Peterson KE; Hasenkrug KJ
Proc Natl Acad Sci U S A; 2004 Aug; 101(33):12260-5. PubMed ID: 15297622
[TBL] [Abstract][Full Text] [Related]
14. Protection against retroviral diseases after vaccination is conferred by interference to superinfection with attenuated murine leukemia viruses.
Corbin A; Sitbon M
J Virol; 1993 Sep; 67(9):5146-52. PubMed ID: 8394442
[TBL] [Abstract][Full Text] [Related]
15. Immunoprotective determinants in friend murine leukemia virus envelope protein.
Hasenkrug KJ; Brooks DM; Robertson MN; Srinivas RV; Chesebro B
Virology; 1998 Aug; 248(1):66-73. PubMed ID: 9705256
[TBL] [Abstract][Full Text] [Related]
16. Cellular and molecular mechanisms of vaccine-induced protection against retroviral infections.
Dittmer U; Hasenkrug KJ
Curr Mol Med; 2001 Sep; 1(4):431-6. PubMed ID: 11899087
[TBL] [Abstract][Full Text] [Related]
17. Interference of retroviral envelope with vaccine-induced CD8
Bongard N; Lapuente D; Windmann S; Dittmer U; Tenbusch M; Bayer W
Retrovirology; 2017 Apr; 14(1):28. PubMed ID: 28449719
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccine against Friend erythroleukaemia virus.
Síma P; Smahel M; Jelínek F; Vonka V
Folia Biol (Praha); 2002; 48(2):43-50. PubMed ID: 12002674
[TBL] [Abstract][Full Text] [Related]
19. T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant.
Earl PL; Moss B; Morrison RP; Wehrly K; Nishio J; Chesebro B
Science; 1986 Nov; 234(4777):728-31. PubMed ID: 3490689
[TBL] [Abstract][Full Text] [Related]
20. Immunization with a murine cytomegalovirus based vector encoding retrovirus envelope confers strong protection from Friend retrovirus challenge infection.
Bongard N; Le-Trilling VTK; Malyshkina A; Rückborn M; Wohlgemuth K; Wensing I; Windmann S; Dittmer U; Trilling M; Bayer W
PLoS Pathog; 2019 Sep; 15(9):e1008043. PubMed ID: 31568492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
